These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 28322590)

  • 1. Randomized Clinical Trials of Gene Transfer for Heart Failure with Reduced Ejection Fraction.
    Penny WF; Hammond HK
    Hum Gene Ther; 2017 May; 28(5):378-384. PubMed ID: 28322590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial.
    Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Desai AS; Barnard D; Bouchard A; Jaski B; Lyon AR; Pogoda JM; Rudy JJ; Zsebo KM
    Lancet; 2016 Mar; 387(10024):1178-86. PubMed ID: 26803443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).
    Greenberg B; Yaroshinsky A; Zsebo KM; Butler J; Felker GM; Voors AA; Rudy JJ; Wagner K; Hajjar RJ
    JACC Heart Fail; 2014 Feb; 2(1):84-92. PubMed ID: 24622121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure: A Randomized Clinical Trial.
    Hammond HK; Penny WF; Traverse JH; Henry TD; Watkins MW; Yancy CW; Sweis RN; Adler ED; Patel AN; Murray DR; Ross RS; Bhargava V; Maisel A; Barnard DD; Lai NC; Dalton ND; Lee ML; Narayan SM; Blanchard DG; Gao MH
    JAMA Cardiol; 2016 May; 1(2):163-71. PubMed ID: 27437887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial.
    Hulot JS; Salem JE; Redheuil A; Collet JP; Varnous S; Jourdain P; Logeart D; Gandjbakhch E; Bernard C; Hatem SN; Isnard R; Cluzel P; Le Feuvre C; Leprince P; Hammoudi N; Lemoine FM; Klatzmann D; Vicaut E; Komajda M; Montalescot G; Lompré AM; Hajjar RJ;
    Eur J Heart Fail; 2017 Nov; 19(11):1534-1541. PubMed ID: 28393439
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term effects of AAV1/SERCA2a gene transfer in patients with severe heart failure: analysis of recurrent cardiovascular events and mortality.
    Zsebo K; Yaroshinsky A; Rudy JJ; Wagner K; Greenberg B; Jessup M; Hajjar RJ
    Circ Res; 2014 Jan; 114(1):101-8. PubMed ID: 24065463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides.
    Zhai Y; Luo Y; Wu P; Li D
    J Med Genet; 2018 May; 55(5):287-296. PubMed ID: 29478009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a Phase 3 trial of intracoronary administration of human adenovirus 5 encoding human adenylyl cyclase type 6 (RT-100) gene transfer in patients with heart failure with reduced left ventricular ejection fraction: The FLOURISH Clinical Trial.
    Penny WF; Henry TD; Watkins MW; Patel AN; Hammond HK
    Am Heart J; 2018 Jul; 201():111-116. PubMed ID: 29763816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL.
    Lyon AR; Babalis D; Morley-Smith AC; Hedger M; Suarez Barrientos A; Foldes G; Couch LS; Chowdhury RA; Tzortzis KN; Peters NS; Rog-Zielinska EA; Yang HY; Welch S; Bowles CT; Rahman Haley S; Bell AR; Rice A; Sasikaran T; Johnson NA; Falaschetti E; Parameshwar J; Lewis C; Tsui S; Simon A; Pepper J; Rudy JJ; Zsebo KM; Macleod KT; Terracciano CM; Hajjar RJ; Banner N; Harding SE
    Gene Ther; 2020 Dec; 27(12):579-590. PubMed ID: 32669717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.
    Jaski BE; Jessup ML; Mancini DM; Cappola TP; Pauly DF; Greenberg B; Borow K; Dittrich H; Zsebo KM; Hajjar RJ;
    J Card Fail; 2009 Apr; 15(3):171-81. PubMed ID: 19327618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.
    Jessup M; Greenberg B; Mancini D; Cappola T; Pauly DF; Jaski B; Yaroshinsky A; Zsebo KM; Dittrich H; Hajjar RJ;
    Circulation; 2011 Jul; 124(3):304-13. PubMed ID: 21709064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial.
    Chung ES; Miller L; Patel AN; Anderson RD; Mendelsohn FO; Traverse J; Silver KH; Shin J; Ewald G; Farr MJ; Anwaruddin S; Plat F; Fisher SJ; AuWerter AT; Pastore JM; Aras R; Penn MS
    Eur Heart J; 2015 Sep; 36(33):2228-38. PubMed ID: 26056125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene therapy for heart failure.
    Greenberg B
    J Cardiol; 2015 Sep; 66(3):195-200. PubMed ID: 25818479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adeno-associated viral gene transfer of SERCA2a improves heart function in chronic congestive heart failure rats].
    Hui HP; Li XY; Liu XH; Sun S; Lu XC; Liu T; Yang W
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Apr; 34(4):357-62. PubMed ID: 16776934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure.
    Tilemann L; Lee A; Ishikawa K; Aguero J; Rapti K; Santos-Gallego C; Kohlbrenner E; Fish KM; Kho C; Hajjar RJ
    Sci Transl Med; 2013 Nov; 5(211):211ra159. PubMed ID: 24225946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in cardiac function after sarcoplasmic reticulum Ca2+-ATPase gene transfer in a beagle heart failure model.
    Mi YF; Li XY; Tang LJ; Lu XC; Fu ZQ; Ye WH
    Chin Med J (Engl); 2009 Jun; 122(12):1423-8. PubMed ID: 19567165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.
    Kawase Y; Ly HQ; Prunier F; Lebeche D; Shi Y; Jin H; Hadri L; Yoneyama R; Hoshino K; Takewa Y; Sakata S; Peluso R; Zsebo K; Gwathmey JK; Tardif JC; Tanguay JF; Hajjar RJ
    J Am Coll Cardiol; 2008 Mar; 51(11):1112-9. PubMed ID: 18342232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Gene therapy in heart failure: the unexpected results from the CUPID 2 trial].
    Gigli M; Sinagra G; Mestroni L
    G Ital Cardiol (Rome); 2017 Feb; 18(2):101-105. PubMed ID: 28398363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.
    Hajjar RJ; Zsebo K; Deckelbaum L; Thompson C; Rudy J; Yaroshinsky A; Ly H; Kawase Y; Wagner K; Borow K; Jaski B; London B; Greenberg B; Pauly DF; Patten R; Starling R; Mancini D; Jessup M
    J Card Fail; 2008 Jun; 14(5):355-67. PubMed ID: 18514926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Overexpression of sarcoplasmic reticulum calcium ATPase induced hemodynamic and proteomic changes in a dog model of heart failure].
    Fu ZQ; Li XY; Liu XH; Sun S; Liu T; Mi YF; Zhou SA; Ye WH; Wang QS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Mar; 36(3):260-5. PubMed ID: 19099986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.